Organovo (NASDAQ:ONVO – Get Free Report) issued its earnings results on Wednesday. The medical research company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.02, Zacks reports. Organovo had a negative net margin of 10,151.64% and a negative return on equity of 266.48%. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.05 million.
Organovo Stock Performance
Shares of NASDAQ:ONVO opened at $0.38 on Friday. The stock’s 50-day moving average is $0.38 and its 200 day moving average is $0.45. Organovo has a 1 year low of $0.32 and a 1 year high of $1.74.
Analyst Ratings Changes
Separately, StockNews.com began coverage on shares of Organovo in a report on Saturday, February 15th. They issued a “sell” rating on the stock.
Organovo Company Profile
Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
Featured Articles
- Five stocks we like better than Organovo
- How to Calculate Retirement Income: MarketBeat’s Calculator
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
- Stock Market Upgrades: What Are They?
- Gold’s Ascent: Can Miners and ETFs Take Investors to $3,000?
- Top Stocks Investing in 5G Technology
- Medtronic’s Expansion Gains Momentum—Time for a Market Shift?
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.
